



## Global Product Development

15 July 2021

Marion Gruber, Ph.D.  
Director  
Food and Drug Administration  
Office of Vaccines Research and Review  
Center for Biologics Evaluation and Research  
c/o Central Document Room  
10903 New Hampshire Avenue, WO71-G112  
Silver Spring, MD 20993-0002

THIS DOCUMENT CONTAINS  
CONFIDENTIAL AND/OR TRADE SECRET  
INFORMATION THAT IS DISCLOSED  
ONLY IN CONNECTION WITH THE  
LICENSING AND/OR REGISTRATION OF  
PRODUCTS FOR PFIZER INC OR ITS  
AFFILIATED COMPANIES. THIS  
DOCUMENT SHOULD NOT BE DISCLOSED  
OR USED, IN WHOLE OR IN PART, FOR  
ANY OTHER PURPOSE WITHOUT THE  
PRIOR WRITTEN CONSENT OF PFIZER  
INC.

**Re: COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736**

**eCTD Sequence 0408**

**Serial No. 0408**

**IND Summary Monthly Safety Report: Reporting Period 01-JUN-2021 – 30-JUN-2021**

Dear Dr. Gruber,

The provided report summarizes information associated with the subject IND during the reporting period. Please note that the format of the IND Annual Report for 2021 has been converted from the format described in 21 CFR 312.33 to the Summary Monthly Safety Report (SMSR) format described in *International Conference on Harmonization; Guideline E2C (R2) Periodic benefit-risk evaluation report (PBREER), Step 5, January 2013*.

This submission has been scanned for viruses using McAfee VirusScan Enterprise Version 8.8 and is virus free. The submission is being sent via the Gateway.

Should you have any questions regarding this submission please contact me via phone at 212-733-2613; or via email at [neda.aghajanimemar@pfizer.com](mailto:neda.aghajanimemar@pfizer.com).

Sincerely,

Neda Aghajani Memar, Pharm.D.  
Director  
Pfizer Global Regulatory Affairs